RELATED RESOURCES
Get all our 2025 Preview content here
Biotech is expected to continue its recovery next year after a sharp decline during the post-pandemic downturn. While a swift resurgence is unlikely in 2025, both investors and companies anticipate increased deal-making and improved access to funding. However, significant uncertainties tied to the US's transition to a new presidential administration are prompting caution in the sector.
Our 2025 Preview Content Hub is your go-to source for all the data, analysis and expert perspectives shaping the year ahead. We break down the key companies, drugs and therapy areas set to lead the way, while exploring what these trends mean for investor sentiment and the sector’s future recovery.
